Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
Smith+Nephew announced that it will release its second quarter and first half 2025 financial results on August 5, 2025. This announcement is significant as it provides insights into the company’s financial performance and strategic positioning in the medical technology industry. The results will be followed by a conference call for financial analysts, highlighting the company’s commitment to transparency and engagement with stakeholders.
The most recent analyst rating on (SNN) stock is a Hold with a $27.27 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats is well-positioned due to strong financial performance and positive earnings call sentiment, highlighting growth and strategic execution. The technical analysis indicates a strong upward trend, although overbought conditions may pose short-term risks. The high P/E ratio suggests potential overvaluation, but the dividend yield adds some appeal for income-focused investors.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company specializing in the repair, regeneration, and replacement of soft and hard tissue. The company operates in three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, Smith+Nephew now operates in around 100 countries and generated annual sales of $5.8 billion in 2024. It is a constituent of the FTSE100.
Average Trading Volume: 894,153
Technical Sentiment Signal: Buy
Current Market Cap: $13.2B
See more insights into SNN stock on TipRanks’ Stock Analysis page.